Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1997-11-26
2000-06-20
Stucker, Jeffrey
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
4242081, 435348, 435 691, 435 693, 536 2372, 536 241, C12P 2106, A61K 3921, C07H 2104, C12Q 170
Patent
active
060776625
ABSTRACT:
The present disclosure provides retrovirus-like particles which comprise retrovirus env proteins, immunogenic compositions comprising retrovirus-like particles, methods for the production of retrovirus-like particles and methods for the protection of an animal or a human from retrovirus infection using the retrovirus-like particles of the present invention.
REFERENCES:
patent: 5462734 (1995-10-01), Letchworth, III et al.
patent: 5541062 (1996-07-01), Smeekens et al.
patent: 5561228 (1996-10-01), Or et al.
patent: 5562909 (1996-10-01), Allcock et al.
patent: 5562910 (1996-10-01), Daynes et al.
patent: 5571531 (1996-11-01), McDermott et al.
Yamshchikov, G.V., et al. "Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system", (1995), Virol. 214:50-58.
Vzorov, A.N., and Compans, R.W. "Assembly and release of SIV Env proteins with full-lenght or truncated cytoplasmic domains", (1996), Virol. 221:22-33.
Luo, L., et al. "Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells", (1990), Virol. 179:874-880.
Porter, D.C., et al. "Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 gag", (1996), J. of Virol. 70(4):2643-2649.
Morikawa, S., et al. "Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors", (1991), Virol. 183:288-297.
Zingler, K. and Littman, D.R. "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases Env incorporation into particles and fusogenicity and infectivity", (1993), J. of Virol. 67(3):2824-2831.
Haffar, O.K., et al. "Inhibition of virus production in peripheral blood mononuclear cells from human immunodeficiency virus (HIV) type 1-seropositive donors by treatment with recombinant HIV-like particles", (1992), J. of Virol. 66(7):4279-4287.
Rovinski, B., et al. "Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: Implications for development of a cross-protective AIDS vaccine", (1992), J. of Virol. 66(7):4003-4012.
Krausslich, H-G., et al. "Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase", (1993), Virol. 192:605-617.
Vzorov, A.N., et al. "Highly immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus-infected cells", (1991), AIDS Res. Hum. Retr. 7(1):29-36.
Haffar, O., et al. "Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system", (1990), J. of Virol. 64(6):2653-2659.
Haffar, O.K., et al. "HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like-gag-env particles", (1991), Virol. 183:487-495.
Delchambre, M., et al. "The GAG precursor of simian immunodeficiency virus assembles into virus-like particles", (1989), EMBO J. 8(9):2653-2660.
Wills, J.W. and Craven R.C. "Form, function, and use of retroviral Gag proteins", (1991), AIDS 5:639-654.
Vincent, M.J., et al. "Characterization of a novel baboon virus closely resembling human t-cell leukemia virus", (1996), Virol. 226:57-65.
Haynes, J.R., et al. "Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines", (1991), AIDS Res. Hum. Retr. 7(1):17-27.
Dong, J. and Hunter, E. "Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system", (1993), Virol. 194:192-199.
Ball, J.M. et al. "EIAV genomic organization: further characterization by sequencing of purified glycoproteins and cDNA," (1988), Virology, 165:601-605.
Chazal, N. et al. "Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway," (1995), J. Virol., 69:365-375.
Boomer, S. et al. "Isolation of a novel subgroup B feline leukemia virus from a cat infected with FeLV-A," (1994), Virology, 204:805-810.
Zhou, W., et al. "Identification of membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 gag protein which interacts with acidic phospholipids", (1994), J. Virol. 68:2556-2569.
Yuan, X. et al. "Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor," (1993), J. Virol., 67:6387-6394.
Yu, X., et al. "The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virus", (1992), J. Virol. 66:4966-4971.
Willey, R.L. et al. "Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160," (1988), Proc. Natl. Acad. Sci. USA, 85:9580-9584.
Wang, B. et al. "Molecular cloning, expression, and biological characterization of an HTLV-II envelope glycoprotein: HIV-1 expression is permissive for HTLV-II induced cell fusion," (1993), AIDS Res. Hum. Retroviruses, 9:849-860.
Vile, R.G., et al. "A murine cell line producing HTLV-I pseudotype virions carrying a selectable marker gene", (1991), Virol. 180:420-424.
Vey, M. et al. "Maturation of the trans-Golgi network protease furin: compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation," (1994), J. Cell Biol., 127:1829-1842.
Spies, C.P., et al. "Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters conformation of the external domain", (1994), J. Virol. 68:585-591.
Schlitz, R., et al. "Equine infectious anemia virus gene expression: characterization of the RNA splicing pattern and the protein products encoded by open reading frames S1 and S2," (1992), J. Virol., 66:3455-3465.
Rushlow, K. et al. "Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus," (1986), Virology, 155:309-321.
Royer, M. et al. "Functional domains of HIV-1 Gag polyprotein expressed in baculovirus-infected cells," (1991), Virology, 184:417-422.
Rohn, J.L., et al. "Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors", (1994), J. Virol. 68:2458-2467.
Ritter, D.G., et al. "Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain," (1993), Virology, 197:255-264.
Pique, C. et al. "Mutations introduced along the HTLV-I envelope gene result in a non-functional protein: a basis for envelope conservation?" (1990), EMBO J., 9:4243-4248.
Pancino, G., et al. "Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties," (1995), Virology, 206:796-806.
Page, K.A. et al. "Analysis of mutations in the V3 domain of gp160 that affedct fusion and infectivity," (1992), J. Virol., 66:524-533.
Overton, H.A., et al. "The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system", (1989), Virol. 170:107-116.
Morikawa, Y. et al. "Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin," (1993), J. Virol., 67:3601-3604.
Mulligan, M.J., et al. "Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types", (1992), J. Virol. 66:3971-3975.
Moore, J., et al. "Which gp160 vaccine?", (1993), Nature 361:503.
Moldoveanu, Z., et al. "Immune Responses to influenza virus in orally and systemically immunized mice", (1989), Curr. Top. Microbiol. Immunol. 146:91-99.
McCune, J.M., et al. "Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus," (1988), Cell, 53:55-67.
Marx, P.A., et al. "Protectio
Compans Richard W.
Yamshchikov Galina V.
Emory University
Park Hankyel T.
Stucker Jeffrey
LandOfFree
Virus-like particles, methods and immunogenic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus-like particles, methods and immunogenic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus-like particles, methods and immunogenic compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1850784